Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Long COVID: What factors contribute to the risk?
Only a minority of patients are considered fully recovered 1 year after being discharged from hospital due to COVID-19, with women and obese individuals at increased risk of long COVID, according to results of the prospective PHOSP-COVID* study presented at ECCMID 2022 and published in The Lancet.
Long COVID: What factors contribute to the risk?
25 May 2022
What is the most preferred first-line agent for paediatric alopecia areata?
In the treatment of paediatric alopecia areata (AA), an autoimmune, nonscarring hair loss disorder with a variable disease course and significant psychosocial impact, the most preferred first-line agent is topical corticosteroids, followed by contact immunotherapy, according to a study.
What is the most preferred first-line agent for paediatric alopecia areata?
25 May 2022
OMDI shows potential as first-line treatment for glaucoma in real-world trial
In a retrospective review of real-world data from Japan, omidenepag isopropyl 0.002% ophthalmic solution (OMDI) demonstrated an intraocular pressure (IOP)-lowering effect in eyes with different types of glaucoma, without severe or serious adverse effects.
OMDI shows potential as first-line treatment for glaucoma in real-world trial
24 May 2022
Fewer hospitalizations with omicron vs delta suggest reduced severity of omicron variant
Infection with the omicron variant of SARS-CoV-2 was less likely to result in hospitalization than infection with the delta variant, according to an observational study from Denmark presented at ECCMID 2022 and published in The Lancet.
Fewer hospitalizations with omicron vs delta suggest reduced severity of omicron variant
23 May 2022
Upadacitinib provides robust, long-term control of moderate-to-severe AD
Follow-up data from two replicate ongoing phase III trials – Measure Up 1 and Measure Up 2 – demonstrated favourable longer-term benefit-risk profile of upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis (AD).